Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis

Area of Science:

• Anesthesiology and Pain Management
• Neurology
• Pharmacology

Background:

• Post-thymectomy pain in myasthenia gravis (MG) patients can lead to respiratory complications.
• Analgesic misuse may worsen respiratory inhibition and trigger myasthenic crisis.
• Flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID), is recognized for managing moderate postoperative pain without respiratory depression.

Purpose of the Study:

• To evaluate the efficacy and safety of flurbiprofen for post-thymectomy pain management in MG patients.
• To compare flurbiprofen with tramadol in controlling postoperative pain and assess respiratory side effects.

Main Methods:

• A randomized controlled trial involving 200 MG patients undergoing extended thymectomy.
• Patients received either intravenous flurbiprofen axetil (50 mg) or intramuscular tramadol (100 mg) for postoperative analgesia.
• Pain scores (VAS), vital signs (heart rate, blood pressure, respiratory rate, SpO2), and adverse events were monitored for 24 hours.

Main Results:

• Both flurbiprofen and tramadol reduced pain significantly (p<0.05).
• Flurbiprofen demonstrated significantly lower VAS pain scores at 0.5, 2, 4, and 8 hours post-surgery (p<0.05).
• No significant changes in heart rate, respiratory rate, mean arterial blood pressure, or SpO2 were observed in either group.

Conclusions:

• Intravenous flurbiprofen axetil is a safe and effective analgesic option for myasthenia gravis patients post-thymectomy.
• Flurbiprofen provides superior pain relief compared to tramadol in this patient population.
• The study supports flurbiprofen's use to mitigate post-thymectomy pain without compromising respiratory function.